Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial to Study the Efficacy and Safety of Insulin Aspart Three Times Per Day Compared to Glibenclamide Once or Twice Daily in Type 2 Diabetes by Comparison of Ability to Control Blood Glucose

NCT00267683 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00267683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00267683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial to Study the Efficacy and Safety of Insulin Aspart Three Times Per Day Compared to Glibenclamide Once or Twice Daily in Type 2 Diabetes by Comparison of Ability to Control Blood Glucose
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2005
Completion date
April 30, 2006
Enrollment
9 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2